News
The CMS last month declined to include anti-obesity medications in its Medicare coverage for Part D, a move that Lilly says ...
Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of ...
Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...
Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...
Cigna’s (NYSE:CI) health services arm, Evernorth, has launched a pharmacy benefit program that caps out-of-pocket costs at ...
The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...
Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.
Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an ...
Cigna subsidiary Evernorth Health Services will automate prior authorizations for GLP-1 weight-loss drugs under a new program ...
The telehealth site will welcome its own small-dose, compounded version of semaglutide, which mimics the function of a GLP-1.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results